Literature DB >> 3018180

Appearance of Guillain-Barré syndrome in patients during corticosteroid treatment.

I Steiner, I Wirguin, O Abramsky.   

Abstract

Three patients developed acute Guillain-Barré syndrome while on steroid treatment. The first patient suffered from ulcerative colitis and developed Guillain-Barré syndrome when the steroid dosage was being tapered. Another patient with long-standing multiple sclerosis received steroids during relapse and the Guillain-Barré syndrome appeared while treatment was reduced. The third patient, with aqueductal stenosis and ventriculoatrial shunt, who received steroids when malfunction of the shunt was suspected, developed Guillain-Barré syndrome while steroids were being tapered. Based on the putative immune pathogenesis of inflammatory demyelinating polyneuropathy, the occurrence of the syndrome in these patients could have been due to a selective effect of low-dose steroids on a specific, maybe suppressor lymphocyte subpopulation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3018180     DOI: 10.1007/bf00314023

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  19 in total

1.  Hapten-specific IgE antibody responses in mice. VI. Selective enhancement of IgE antibody production by low doses of X-irradiation and by cyclophosphamide.

Authors:  N Chiorazzi; D A Fox; D H Katz
Journal:  J Immunol       Date:  1976-11       Impact factor: 5.422

2.  THE GUILLAIN-BARR'E SYNDROME ASSOCIATED WITH CANCER.

Authors:  G H KLINGON
Journal:  Cancer       Date:  1965-02       Impact factor: 6.860

3.  Guillain-Barré syndrome and Hodgkin's disease: three cases with immunological studies.

Authors:  R P Lisak; M Mitchell; B Zweiman; E Orrechio; A K Asbury
Journal:  Ann Neurol       Date:  1977-01       Impact factor: 10.422

4.  Cell-mediated demyelination of peripheral nerve in tissue culture.

Authors:  B G Arnason; G F Winkler; N M Hadler
Journal:  Lab Invest       Date:  1969-07       Impact factor: 5.662

5.  The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis.

Authors:  A K Asbury; B G Arnason; R D Adams
Journal:  Medicine (Baltimore)       Date:  1969-05       Impact factor: 1.889

6.  Enhancing effect of low dose cyclophosphamide treatment on the in vitro antibody response.

Authors:  H Duclos; P Galanaud; O Devinsky; M C Maillot; J Dormont
Journal:  Eur J Immunol       Date:  1977-10       Impact factor: 5.532

7.  Association with autoimmune diseases and cellular immune response to the neuritogenic protein in Guillain-Barré syndrome.

Authors:  O Abramsky; I Korn-Lubetzky; D Teitelbaum
Journal:  Trans Am Neurol Assoc       Date:  1980

8.  Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE.

Authors:  Z Lando; D Teitelbaum; R Arnon
Journal:  J Immunol       Date:  1979-11       Impact factor: 5.422

9.  Polyradicular neuritis and Hashimoto's thyroiditis.

Authors:  G Potz; B Neundörfer
Journal:  J Neurol       Date:  1975-10-24       Impact factor: 4.849

10.  The Landry-Guillain-Barré syndrome and pregnancy.

Authors:  G Ahlberg; G Ahlmark
Journal:  Acta Obstet Gynecol Scand       Date:  1978       Impact factor: 3.636

View more
  3 in total

Review 1.  Transient immunosuppression: a bridge between infection and the atypical autoimmunity of Guillain-Barré syndrome?

Authors:  I Steiner; G Rosenberg; I Wirguin
Journal:  Clin Exp Immunol       Date:  2010-10       Impact factor: 4.330

2.  A Korean patient with Guillain-Barré syndrome following acute hepatitis E whose cholestasis resolved with steroid therapy.

Authors:  Sung Bok Ji; Sang Soo Lee; Hee Cheul Jung; Hong Jun Kim; Hyun Jin Kim; Tae Hyo Kim; Woon Tae Jung; Ok Jae Lee; Dae Hyun Song
Journal:  Clin Mol Hepatol       Date:  2016-08-30

3.  Guillain-Barré syndrome as an extraintestinal manifestation of Crohn's disease.

Authors:  R de la Fuente-Fernández; E Rubio-Nazabal; F de la Iglesia-Martínez
Journal:  Postgrad Med J       Date:  1995-07       Impact factor: 2.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.